Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 18/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 15/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819968 | 0.83 | HRH1 (0.74) | HRH1ADRA1AADRA1BHRH3KCNH2 | |
| SCHEMBL2779878 | 0.83 | HRH1 (0.74) | HRH1ADRA1AADRA1BHRH3KCNH2 | |
| SCHEMBL2824664 | 0.76 | HRH1 (0.77) | HRH1ADRA1AADRA1BHRH3KCNH2 | |
| SCHEMBL2821532 | 0.72 | MERTK (0.42) | HRH1ADRA1AADRA1BHRH3KCNH2 | |
| SCHEMBL18426382 | 0.71 | LMNA (0.48) | — | |
| SCHEMBL18426380 | 0.71 | LMNA (0.48) | — | |
| SCHEMBL23914736 | 0.71 | MAPT (0.52) | HRH1ADRA1AADRA1BHRH3KCNH2 | |
| SCHEMBL5430075 | 0.70 | HRH3 (0.48) | HRH3KCNH2 | |
| SCHEMBL20956786 | 0.70 | HRH3 (0.48) | HRH3KCNH2 | |
| SCHEMBL27752421 | 0.69 | HRH1 (0.69) | HRH1ADRA1AADRA1BHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007735-B1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| CN-101472899-A | 2-substituted 4-benzylphthalazinone derivatives as histamine H1 and H3 antagonists | GLAXO GROUP LTD (GB) | 2009-07-01 | — | — | CN | disclosed |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20080039444-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039444-A1 | COMPOUNDS | CMA1, MRGPRX2, HRH2 | HRH1 4/4885ADRA1A 362/4885ADRA1B 308/4885 |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | HRH2, HRH3, HRH4 | HRH1 4/4885ADRA1A 150/4885ADRA1B 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.